jRCT1041210141进行中（未招募）不适用
The effect of roxadustat on erythropoietin production from liver among patients on long-term maintenance hemodialysis or patients with non-dialysis dependent chronic kidney disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 主要终点
- Proportion of erythropoietin derived from kidneys or liver
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20age old over 至 95age old not（—）
- 性别
- All
入选标准
- •Hemodialysis patients
- •age>=20 and <95
- •dialysis vintage > 15 years
- •receiving treatment with erythropoiesis stimulating agents (ESA)
- •requiring change from ESA to HIF-PH inhibitors for clinical reasons
- •those who consent to participation to the research
- •Patients with non-dialysis dependent chronic kidney disease
- •age>=20 and <95
- •receiving treatment with ESA
- •requiring change from ESA to HIF-PH inhibitors for clinical reasons
- •those who consent to participation to the research
排除标准
- •Those with malignancy
- •Those with deep venous thrombosis
- •Hematologic malignancy including myelodysplastic syndrome
- •Iron deficiency (transferrin saturation <20% or ferritin <100ng/mL)
- •Active bleeding
- •Liver dysfunction (Child Pugh class B or C)
- •Diabetic proliferative retinopathy
- •Those who were deemed to be ineligible by treating physicians
结局指标
主要结局
Proportion of erythropoietin derived from kidneys or liver
时间窗: 1-2 week and 12 weeks
Proportion of erythropoietin derived from kidneys or liver after switching from ESA to roxadustat
次要结局
- Proportion of patients achieving target hemoglobin of 10-12g/dL(12 weeks after initiation of roxadustat)
- hemogloin levels(12 weeks after initiation of roxadustat)
- erythroferron levels(12 weeks after initiation of roxadustat)
- hepcidin levels(12 weeks after initiation of roxadustat)
研究者
相似试验
进行中（未招募）
不适用
Roxadustat and hepatic erythropoetin productioRenal anemiarenal anemia, chronic kidney disease, roxadustat, erythropoietinJPRN-jRCT1041210141Hamano Takayuki40
已完成
不适用
Effect of roxadustat on erythropoiesis and iron metabolismrenal anemiaJPRN-UMIN000045857Showa University34
招募中
4 期
Recombinant Human Erythropoietin Increasing Hemoglobin Level and Reducing Blood Transfusion in Femoral Fracture Patients : A Double-Blinded Randomized Controlled Trial Studyhemoglobin loss in femoral fracture patientblood transfusionhemoglobin levelTCTR20230117005Faculty of medicine vajira hospital50
已完成
不适用
Effects of erythropoiesis stimulating agentin on heart failure patients with reduced left ventricular function and the cardiorenal anemia syndromeChronic heart failure patients with reduced left ventricular functionJPRN-UMIN000010762Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine100
已完成
4 期
Effects of erythropoietin stimulating agent on quality of life in non-dialysis ESRD patientsQuality of LifeKidney Failure, ChronicQuality of life in non dialysis chronic kidney disease who receive and not receive erythropoiesis stimulating agentHematinicsAnemiaTCTR20231103005Phayao hospital58